DGAP-News

Neovacs S.A.: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship

DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous
Neovacs S.A.: Stellar Biotechnologies and Neovacs S.A. Expand KLH
Supply Relationship

01.04.2015 / 08:00

---------------------------------------------------------------------


Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship

Companies Sign KLH Supply Agreement for Neovacs' Kinoid Clinical Trials and
Initial Commercialization

PORT HUENEME, CA and PARIS, FRANCE, (April 1st, 2015) -- Stellar
Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX-V:
KLH) and Neovacs S.A., ("Neovacs") (Alternext Paris: ALNEV) today announced
that the Companies have entered into an expanded supply agreement to meet
Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary
component of Neovacs' proprietary Kinoid immunotherapy technology.

The new agreement extends and expands the supply contracts previously in
place between the Companies, in order to ensure the continued supply of
Stellar KLH(TM) to Neovacs during its Kinoid clinical trials and to support
the expected commercial roll-out of Neovacs' lead product candidate
IFNα-Kinoid, an immunotherapy being developed for the treatment of systemic
lupus erythematosus ("lupus").

Stellar is a leader in the sustainable manufacture of KLH, an
immune-stimulating protein widely used as a carrier molecule in
immunotherapies under development for a variety of disease indications.
Immunotherapy uses a patient's own immune system to target and treat
diseases. KLH can only be produced from a scarce marine source. Stellar
believes it is the only company with the proprietary technology to manage
sustainable, scalable production of GMP quality KLH to meet future
pharmaceutical industry demands.

Neovacs is a leader in the development of active immunotherapies for the
treatment of chronic autoimmune diseases. Neovacs' patented Kinoid
technology combines a select cytokine of interest attached to KLH as the
immune-stimulating carrier protein. The resulting immunotherapy uses the
patient's immune system to generate antibodies against the targeted
disease.

Neovacs' lead product candidate, IFN(-Kinoid, has successfully completed a
Phase I/IIa clinical trial for lupus. The Company's Scientific Advisory
Board (SAB) members have announced their full support for the planned Phase